NuroKor Australian Market welcomes Gemma Fitzsimons
NuroKor Biolectronics is excited to announce the new appointment of Gemma Fitzsimons who joins as General Manager for the Australian market.
The new addition to the Australian team is set to aid NuroKor in its vision to continue developing science and medical technology that puts the power of cutting-edge bioelectronics directly into the hands of the Australian consumer.
"I am thrilled to be part of such a dynamic team that is truly disrupting the way we treat pain and injury. With more than 3 million Australians currently living with chronic pain I'm excited to drive awareness of the NuroKor brand and help transform the lives of many of these people, with a natural, non-invasive personalised treatment technology."
An advocate of natural to the body therapies, Gemma has worked across multiple markets including the UK and Australia and brings with her over fifteen years of experience in the retail industry working for major brands. A highly creative, curious and strategic leader, she is driven by purpose both professionally and personally and has a wealth of experience across brand strategy, multi-channel marketing, loyalty and customer experience.
Gemma is very much looking forward to contributing to the NuroKor brand and making an impact to others wellbeing and quality of life, be it for pain relief, recovery or to enhance performance. As a former elite swimmer who had to retire early due to injury she understands the impact pain can have both on your physical and emotional health.
Sharing her enthusiasm for the role, Gemma said:
"I feel privileged to be part of such an innovative company who is leading the charge in bioelectronic technology and driving the next revolution in healthcare. I can't wait to bring the NuroKor brand to market and help thousands of Aussies be ready for more with our electroceutical therapy devices."
Founded in 2018, NuroKor is a business committed to the development of bioelectronic technologies. NuroKor develops and formulates programmable bioelectronic software for clinical and therapeutic applications, in a range of easy to use, wearable devices. It provides the highest-quality, medically regulated products, delivering personalised pain relief and recovery support and rehabilitation to patients.